2'-O-Methyl Oligoribonucleotide Analogs Used to Change the Temperature Characteristics of Immobilized Probes and to Enhance the Specificity of Hybridization

[1]  Christina Kratschmer,et al.  Effect of Chemical Modifications on Aptamer Stability in Serum. , 2017, Nucleic acid therapeutics.

[2]  S. Lapa,et al.  The Effect of the Structure of Fluorescently Labeled Nucleotide Derivatives on the Efficiency of Their Incorporation in DNA in the Polymerase Chain Reaction , 2017 .

[3]  V. Barsky,et al.  Microarray analyzer based on wide field fluorescent microscopy with laser illumination and a device for speckle suppression. , 2017, Biomedical optics express.

[4]  A. Mishra,et al.  Peptide nucleic acids: Advanced tools for biomedical applications , 2017, Journal of Biotechnology.

[5]  A. Kudryavtseva,et al.  Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis , 2017, Oncotarget.

[6]  D. Turner,et al.  Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication , 2016, Nucleic acid therapeutics.

[7]  Christopher J. Krueger,et al.  Single-molecule detection and tracking of RNA transcripts in living cells using phosphorothioate-optimized 2'-O-methyl RNA molecular beacons. , 2016, Biomaterials.

[8]  R. Kierzek,et al.  Structural Aspects of the Antiparallel and Parallel Duplexes Formed by DNA, 2’-O-Methyl RNA and RNA Oligonucleotides , 2015, PloS one.

[9]  A. Zasedatelev,et al.  Microarray with LNA-probes for genotyping of polymorphic variants of Gilbert’s syndrome gene UGT1A1(TA)n , 2012, Clinical chemistry and laboratory medicine.

[10]  S. Obika,et al.  Antisense drug discovery and development. , 2011, Future medicinal chemistry.

[11]  Sergei M Gryaznov,et al.  Oligonucleotide N3′→P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents , 2010, Chemistry & biodiversity.

[12]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[13]  V. Baranov,et al.  Development of a Biochip for Analyzing Polymorphism of the Biotransformation Genes , 2005, Molecular Biology.

[14]  J. Wengel,et al.  LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. , 2004, Biochemistry.

[15]  Gang Bao,et al.  Hybridization of 2'-O-methyl and 2'-deoxy molecular beacons to RNA and DNA targets. , 2002, Nucleic acids research.

[16]  Y. Cho‐Chung.  Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic , 2000 .

[17]  P. D. Cook,et al.  Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. , 1993, Journal of medicinal chemistry.

[18]  G. Zon,et al.  Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers. , 1991, Nucleic acids research.

[19]  M. Reitz,et al.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Maruyama,et al.  Designing Effective Antisense Oligonucleotides for Exon Skipping. , 2018, Methods in molecular biology.

[21]  G. Duff,et al.  Modulation of interleukin 1 beta gene expression using antisense phosphorothioate oligonucleotides. , 1990, Lymphokine research.